Does high blood pressure increase stroke risk?
Strong EvidenceYES
Overwhelming evidence from prospective studies involving over 1 million participants and meta-analyses of treatment trials establishes hypertension as the single strongest modifiable risk factor for stroke, with a continuous dose-response relationship.
The Verdict
Overwhelming evidence from prospective studies involving over 1 million participants and meta-analyses of treatment trials establishes hypertension as the single strongest modifiable risk factor for stroke, with a continuous dose-response relationship.
What the Evidence Shows
The causal relationship between blood pressure and stroke is one of the most robust findings in cardiovascular epidemiology. The Prospective Studies Collaboration, analyzing individual data from nearly 1 million adults across 61 studies, demonstrated a continuous, log-linear relationship between blood pressure and stroke risk starting from 115/75 mmHg—with no lower threshold below which risk disappears. Each 20 mmHg higher systolic blood pressure approximately doubles stroke risk across all age groups studied. Treatment trials have confirmed causality: Law and colleagues' meta-analysis of 147 RCTs showed that blood pressure lowering reduces stroke risk by approximately 35-40% for a 10 mmHg reduction in systolic pressure, with benefits proportional to the magnitude of blood pressure reduction regardless of the drug class used. Ettehad's more recent comprehensive meta-analysis confirmed these findings across diverse populations and treatment strategies. The mechanisms are well-characterized: chronic hypertension causes arterial remodeling, endothelial dysfunction, accelerated atherosclerosis of cerebral arteries, and promotes formation of small-vessel disease (lipohyalinosis) leading to both ischemic and hemorrhagic stroke subtypes.
Evidence Quality
4
Meta-Analyses
30
RCTs
15
Observational
Important Caveats
- ⚠️ Optimal blood pressure targets remain debated—intensive lowering may increase adverse events in some populations
- ⚠️ Absolute risk reduction depends on baseline cardiovascular risk—treatment benefits are greatest in high-risk patients
- ⚠️ Blood pressure measurement variability can lead to misclassification—ambulatory monitoring is more accurate
- ⚠️ Some populations (elderly, those with extensive atherosclerosis) may not benefit from aggressive lowering
- ⚠️ Stroke prevention requires sustained blood pressure control—intermittent treatment provides limited protection
Population Studied
Nearly 1 million adults aged 40-89 across 61 prospective observational studies (Lewington); 464,000+ participants in 147 RCTs (Law); 613,815 participants in 123 trials (Ettehad)
Dosage
Each 10 mmHg reduction in systolic blood pressure reduces stroke risk by ~35-40%; target generally <130/80 mmHg for most adults per current guidelines
Duration
Prospective Studies Collaboration: mean 12.7 years follow-up; treatment trials: 2-6 years; stroke risk reduction begins within months of achieving blood pressure control
Supporting Studies (3)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
Meta-AnalysisLewington S, Clarke R, Qizilbash N, Peto R, Collins R (Prospective Studies Collaboration). · Lancet (2002)
Individual data from 958,074 adults showed a continuous log-linear relationship between blood pressure and stroke mortality from 115/75 mmHg upward, with each 20 mmHg higher systolic pressure associated with approximately doubling of stroke death rate.
View paper (DOI) →Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
Meta-AnalysisLaw MR, Morris JK, Wald NJ. · BMJ (2009)
Meta-analysis of 147 RCTs found blood pressure lowering reduces stroke risk by 41% for a 10 mmHg systolic reduction, with benefits consistent across all drug classes, baseline blood pressure levels, and presence or absence of prior cardiovascular disease.
View paper (DOI) →Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
Meta-AnalysisEttehad D, Emdin CA, Kiran A, et al. · Lancet (2016)
Meta-analysis of 123 trials (613,815 participants) confirmed every 10 mmHg reduction in systolic blood pressure significantly reduces stroke (27%), heart disease (17%), heart failure (28%), and all-cause mortality (13%).
View paper (DOI) →Contradicting Studies (1)
Blood pressure targets for hypertension in older adults
Meta-AnalysisArguedas JA, Leiva V, Wright JM. · Cochrane Database of Systematic Reviews (2013)
Cochrane review found no strong evidence that treating to lower blood pressure targets (<135/85 mmHg) reduces mortality or morbidity compared to standard targets (<140-160/90-100 mmHg) in adults with hypertension.
Why this disagrees:
While not disputing that hypertension causes stroke, this review questions whether intensive blood pressure lowering beyond standard thresholds provides additional clinical benefit, suggesting diminishing returns and potential harms from overtreatment, particularly in elderly populations.
Related Claims
Does daily aspirin prevent first heart attacks in healthy people?
Weak EvidenceCurrent evidence shows daily aspirin does NOT provide net benefit for primary prevention in healthy people. Modern trials (ASPREE, ARRIVE) demonstrate that bleeding risks outweigh any modest cardiovascular benefit in low-risk populations.
Does the Mediterranean diet reduce cardiovascular risk?
Strong EvidenceStrong evidence from large RCTs and meta-analyses shows the Mediterranean diet significantly reduces cardiovascular events, including heart attacks and strokes, by approximately 30% compared to control diets.
Do statins reduce heart attack risk?
Strong EvidenceVery strong evidence from large meta-analyses of randomized trials demonstrates that statins reduce major cardiovascular events by approximately 20-25% per 1 mmol/L reduction in LDL cholesterol, with consistent benefits across diverse populations.